

Immuno-oncology in lung cancer: new data and implications for long-term patient management

Monday 22 November 2021

19:30–21:00 (SGT)

Channel 1



AstraZeneca warmly invites you to this symposium to discuss the latest data for immunotherapy in extensive-stage SCLC and unresectable Stage III NSCLC and the implications for long-term management of patients. Pre-recorded presentations will be delivered and discussions moderated by our expert faculty.

We hope you can join us for these discussions and the live Q&A.

Faculty

Ross Soo

Singapore, Singapore
(Chair)

Shankar Siva

Melbourne, Australia

Terufumi Kato

Yokohama, Japan

Agenda

Welcome and introductions

Ross Soo, Chair

Reviewing the treatment landscape in unresectable Stage III NSCLC

Shankar Siva

Extensive-stage SCLC: emerging data and future perspectives

Terufumi Kato

Case study discussion: long-term management of lung cancer patients and considerations for clinical practice

All faculty

Closing remarks

Ross Soo, Chair

Live Q&A session

All faculty (Live audience Q&A session)
